Singulex files for a $86 million IPO


Shutterstock photo

Singulex, which develops innovative tests for the diagnosis and monitoring of chronic diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Alameda, CA-based company, which was founded in 1997 and booked $38 million in sales for the 12 months ended 6/30/2012, plans to list on the NYSE under the symbol SGLX. UBS Investment Bank and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by